New Heart-Lung device could save kids with severe heart failure

NCT ID NCT06080074

First seen Jun 25, 2026 · Last updated Aug 11, 2026 · Updated 4 times

Summary

This study tests a compact heart-lung machine called Cardiohelp in 50 children with severe heart failure. The device supports the heart for up to 30 days while kids recover or await a transplant. The trial also compares two blood thinners to see which causes fewer bleeding or clotting problems. The goal is to get the device FDA-approved for children.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Cardiohelp device (VA-ECMO) and blood thinners (heparin or bivalirudin)
What this could lead to
If successful, this could lead to FDA approval of the Cardiohelp device for longer-term use in children with severe heart failure, and identify a safer blood thinner for these patients.
What could go wrong
This is a Phase 2 trial with only 50 children, so results are preliminary. The device is used off-label, and risks like stroke, bleeding, and organ failure are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOGENIC SHOCK are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Children's Health Dallas

    RECRUITING

    Dallas, Texas, 95235, United States

  • Cuimc/Nyph

    RECRUITING

    New York, New York, 10032, United States

  • Duke University Hospital

    RECRUITING

    Durham, North Carolina, 27710, United States

  • Lucile Packard Children's Hospital

    RECRUITING

    Palo Alto, California, 94304, United States

  • Seattle Children's Hospital

    RECRUITING

    Seattle, Washington, 98105, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.